Publications

BibTex format

@article{Zhang:2018:10.1097/SLA.0000000000002801,
author = {Zhang, D-F and Su, X and Meng, Z-T and Li, H-L and Wang, D-X and Li, X-Y and Maze, M and Ma, D},
doi = {10.1097/SLA.0000000000002801},
journal = {Ann Surg},
title = {Impact of Dexmedetomidine on Long-term Outcomes After Noncardiac Surgery in Elderly: 3-Year Follow-up of a Randomized Controlled Trial.},
url = {http://dx.doi.org/10.1097/SLA.0000000000002801},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVES: The aim was to compare the long-term outcomes of low-dose dexmedetomidine versus placebo in a randomized controlled trial (ChiCTR-TRC-10000802). BACKGROUND: Low-dose dexmedetomidine infusion decreased delirium occurrence within 1 week after surgery in elderly admitted to the intensive care unit (ICU) after noncardiac surgery, but the long-term outcome of this intervention is unknown. METHODS: Patients or their family members were telephone-interviewed for a 3-year follow-up data collection of survival, cognitive function assessed with the modified Telephone Interview for Cognitive Status, and quality of life evaluated with the World Health Organization Quality of Life. RESULTS: Of the 700 patients, 23 (3.3%) were lost at 3-year follow-up. The 3-year overall survival was not statistically different between the dexmedetomidine and placebo groups [114 deaths vs 122/350; hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.68-1.13, P = 0.303]. The survival rates at 6 months, 1 year, and 2 years were significantly higher in the dexmedetomidine than in the placebo group (rate difference of 5.2%, 5.3%, and 6.7% respectively; all P < 0.05). The remaining 98.4% (434/441) 3-year survivors, the dexmedetomidine group, had significantly better cognitive function (mean difference 4.7, 95% CI 3.8-5.6, P < 0.0001) and quality of life (physical domain: 13.6 [10.6-16.6]; psychological domain: 15.2 [12.5-18.0]; social relationship domain: 8.1 [5.5-10.7]; environment domain: 13.3 [10.9-15.7]; all P < 0.0001) than in the placebo group. CONCLUSIONS: For elderly admitted to ICU after noncardiac surgery, low-dose dexmedetomidine infusion did not significantly change 3-year overall survival, but increased survival up to 2 years, and improved cognitive function and quality of life in 3-year survivors.
AU  - Zhang,D-F
AU  - Su,X
AU  - Meng,Z-T
AU  - Li,H-L
AU  - Wang,D-X
AU  - Li,X-Y
AU  - Maze,M
AU  - Ma,D
DO  - 10.1097/SLA.0000000000002801
PY  - 2018///
TI  - Impact of Dexmedetomidine on Long-term Outcomes After Noncardiac Surgery in Elderly: 3-Year Follow-up of a Randomized Controlled Trial.
T2  - Ann Surg
UR  - http://dx.doi.org/10.1097/SLA.0000000000002801
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29742525
ER  -

Download

Professor Daqing Ma, MD, PhD

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)